Dr. Luke D. Maese
Claim this profilePrimary Children's Hospital
Studies Brain Tumor
Studies Leukemia
23 reported clinical trials
56 drugs studied
About Luke D. Maese
Education:
- Obtained MD from the University of Utah School of Medicine in 2015.
- Completed Residency in Pediatrics at the University of Utah in 2018.
- Finished Fellowship in Pediatric Cardiology at the University of Utah in 2021.
Experience:
- Board certified in Pediatrics and Pediatric Cardiology by the American Board of Pediatrics.
- Affiliated with Primary Children's Hospital.
Area of expertise
1Brain Tumor
Stage I
Stage II
Stage IV
2Leukemia
Philadelphia chromosome positive
BCR-ABL1 fusion positive
ABL-class fusion positive
Affiliated Hospitals
Clinical Trials Luke D. Maese is currently running
Selumetinib vs. Chemotherapy
for Brain Cancer
This trial is comparing a new drug, selumetinib, with standard chemotherapy to treat patients with a specific type of brain tumor. The patients do not have a certain genetic mutation and are not affected by a genetic disorder. Selumetinib works by blocking enzymes needed for tumor growth, while the standard drugs kill or stop tumor cells from dividing.
Recruiting2 awards Phase 3
Inotuzumab Ozogamicin
for Acute Lymphoblastic Leukemia
This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. This trial also studies the outcomes of patients with mixed phenotype acute leukemia (MPAL), and B-lymphoblastic lymphoma (B-LLy) when treated with ALL therapy without inotuzumab ozogamicin. Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a type of chemotherapy called calicheamicin. Inotuzumab attaches to cancer cells in a targeted way and delivers calicheamicin to kill them. Other drugs used in the chemotherapy regimen, such as cyclophosphamide, cytarabine, dexamethasone, doxorubicin, daunorubicin, methotrexate, leucovorin, mercaptopurine, prednisone, thioguanine, vincristine, and pegaspargase or calaspargase pegol work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial will also study the outcomes of patients with mixed phenotype acute leukemia (MPAL) and disseminated B lymphoblastic lymphoma (B-LLy) when treated with high-risk ALL chemotherapy. The overall goal of this study is to understand if adding inotuzumab ozogamicin to standard of care chemotherapy maintains or improves outcomes in High Risk B-cell Acute Lymphoblastic Leukemia (HR B-ALL). The first part of the study includes the first two phases of therapy: Induction and Consolidation. This part will collect information on the leukemia, as well as the effects of the initial treatment, to classify patients into post-consolidation treatment groups. On the second part of this study, patients with HR B-ALL will receive the remainder of the chemotherapy cycles (interim maintenance I, delayed intensification, interim maintenance II, maintenance), with some patients randomized to receive inotuzumab. The patients that receive inotuzumab will not receive part of delayed intensification. Other aims of this study include investigating whether treating both males and females with the same duration of chemotherapy maintains outcomes for males who have previously been treated for an additional year compared to girls, as well as to evaluate the best ways to help patients adhere to oral chemotherapy regimens. Finally, this study will be the first to track the outcomes of subjects with disseminated B-cell Lymphoblastic Leukemia (B-LLy) or Mixed Phenotype Acute Leukemia (MPAL) when treated with B-ALL chemotherapy.
Recruiting2 awards Phase 3
More about Luke D. Maese
Clinical Trial Related4 years of experience running clinical trials · Led 23 trials as a Principal Investigator · 13 Active Clinical TrialsTreatments Luke D. Maese has experience with
- Cyclophosphamide
- Radiation Therapy
- Etoposide
- Dexamethasone
- Pegaspargase
- Prednisolone
Breakdown of trials Luke D. Maese has run
Brain Tumor
Leukemia
Lymphoblastic Leukemia-Lymphoma
Acute Lymphoblastic Leukemia
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Luke D. Maese specialize in?
Luke D. Maese focuses on Brain Tumor and Leukemia. In particular, much of their work with Brain Tumor has involved Stage I patients, or patients who are Stage II.
Is Luke D. Maese currently recruiting for clinical trials?
Yes, Luke D. Maese is currently recruiting for 12 clinical trials in Salt Lake City Utah. If you're interested in participating, you should apply.
Are there any treatments that Luke D. Maese has studied deeply?
Yes, Luke D. Maese has studied treatments such as Cyclophosphamide, Radiation Therapy, Etoposide.
What is the best way to schedule an appointment with Luke D. Maese?
Apply for one of the trials that Luke D. Maese is conducting.
What is the office address of Luke D. Maese?
The office of Luke D. Maese is located at: Primary Children's Hospital, Salt Lake City, Utah 84113 United States. This is the address for their practice at the Primary Children's Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.